Should accelerated-approved drugs be priced differently?
The FDA’s accelerated approval review process includes mandatory post-approval trials to confirm a drug’s efficacy. This can lead to situations in which private payers may choose not to cover a drug due to high cost and lack of evidence of clinical efficacy, while major government payers are forced to cover the drug. One solution would be for manufacturers to offer additional price concessions to public insurance programs until the post-approval trials are completed.
Are you for or against?
Last Answered: Over a month ago